Serm short note for 6 marks
Asking for Preferences
1
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have rich content. Let me compile the full short note.
SERMs - Selective Estrogen Receptor Modulators
Definition
SERMs are a class of drugs that bind to estrogen receptors (ERs) and act as agonists or antagonists depending on the target tissue. Unlike pure estrogen agonists or antagonists, they display tissue-selective activity - agonist in some tissues and antagonist in others.
Mechanism of Action
- Estrogen receptors (ER-alpha and ER-beta) are intracellular (cytosolic) receptors.
- SERMs compete with endogenous estrogen for binding to these receptors.
- The drug-receptor complex recruits different co-activator or co-repressor proteins depending on the tissue type, leading to tissue-selective agonist or antagonist effects.
- This tissue selectivity is the basis for their clinical utility - they can block estrogenic effects in some tissues (e.g., breast) while mimicking estrogen in others (e.g., bone).
Key Drugs and Their Tissue-Specific Effects
| Drug | Breast | Bone | Uterus | Other |
|---|---|---|---|---|
| Tamoxifen | Antagonist (anti-tumor) | Agonist (protects BMD) | Agonist (risk of endometrial cancer) | - |
| Raloxifene | Antagonist (reduces cancer risk) | Agonist (prevents osteoporosis) | Neutral/Antagonist (no uterine stimulation) | - |
| Clomiphene | Antagonist (blocks hypothalamic ER) | - | - | Increases GnRH/FSH/LH - induces ovulation |
| Toremifene | Antagonist (similar to tamoxifen) | Agonist | Mild agonist | Breast cancer (alternative to tamoxifen) |
Clinical Uses
-
Tamoxifen
- Treatment and prevention of ER-positive breast cancer (pre- and post-menopausal)
- Adjuvant therapy for 5 years post-surgery
- Route: Oral
-
Raloxifene
- Prevention and treatment of postmenopausal osteoporosis
- Reduces risk of invasive breast cancer in high-risk postmenopausal women
- Does NOT stimulate the uterus (advantage over tamoxifen)
-
Clomiphene
- Ovulation induction in anovulatory infertility (first-line)
- Blocks hypothalamic estrogen receptors → increases GnRH → increases FSH/LH → follicular development
-
Toremifene - Breast cancer (alternative to tamoxifen in postmenopausal women)
Adverse Effects
Tamoxifen:
- Hot flashes, nausea, vomiting
- Vaginal bleeding/discharge
- Endometrial cancer (uterine agonist effect - most important)
- Thromboembolic events (DVT, pulmonary embolism)
- Hypercalcemia (early in treatment)
Raloxifene:
- Hot flashes
- Thromboembolic events (class effect)
- Does NOT cause endometrial cancer (key advantage over tamoxifen)
- Leg cramps
Clomiphene:
- Ovarian hyperstimulation syndrome (OHSS)
- Multiple pregnancies
- Visual disturbances
- Hot flashes
Contraindications
- Tamoxifen: History of thromboembolic disease, pregnancy
- Raloxifene: Premenopausal women, active thromboembolic disease, pregnancy
- Clomiphene: Ovarian cysts, hepatic disease, pregnancy
Summary Comparison: Tamoxifen vs Raloxifene
| Feature | Tamoxifen | Raloxifene |
|---|---|---|
| Breast cancer treatment | Yes (pre + post-menopausal) | Prevention only (post-menopausal) |
| Osteoporosis | Yes (side benefit) | Yes (primary indication) |
| Endometrial cancer risk | Increased | No increase |
| Thromboembolic risk | Increased | Increased |
| Use in premenopausal women | Yes | No |
Sources: Lippincott Illustrated Reviews Pharmacology, Chapter 37; Goldman-Cecil Medicine; Rheumatology 2-Volume Set (Elsevier, 2022)
This is a shared conversation. Sign in to Orris to start your own chat.